News ArticleGSK India Posts 21% Revenue Rise to INR 1180 Crore and 31% Profit Growth in Q2 FY2027 Led by Oncology and Vaccines Expansion
Strong performance supported by innovation portfolio evolution, lifecycle management, and full year of oncology commercialization
GlaxoSmithKline Pharmaceuticals Limited India achieved 21% year-on-year revenue growth to INR 1180 crore and 31% profit after tax increase to INR 335 crore in Q2 FY2027, driven by robust growth across General Medicines, Vaccines, and Oncology businesses, supported by product line extensions and expanded specialty portfolio including a haemato-oncology launch.
GlaxoSmithKline Pharmaceuticals Limited
General / Other
GlaxoSmithKline Pharmaceuticals Limited India reported a 21% increase in revenue to INR 1180 crore and a 31% rise in profit after tax to INR 335 crore for the quarter ended 30th September 2026, driven by growth across General Medicines, Vaccines, and Oncology portfolios.
The company's General Medicines portfolio saw robust growth with key promoted brands such as Augmentin, Calpol, Ceftum, and T-bact gaining market share and leadership through focused scientific engagement. Calpol 500 Suspension and Eltroxin formulations were introduced as line extensions to address precise dosing needs.
The Vaccines business expanded, maintaining leadership in the private paediatric vaccines market and advancing adult vaccination awareness, notably increasing uptake of Shingrix for adults over 50 years, supported by a public preventive healthcare campaign including a Guinness World Record event for healthy ageing awareness.
The Oncology portfolio accelerated, with full-year market presence for Jemperli and Zejula treatments addressing unmet needs in gynaecological cancers. The company is also entering haemato-oncology with BLENREP, an anti-BCMA antibody-drug conjugate for relapsed or refractory multiple myeloma, launched during the period.
Highlights
- Q2 FY2027 revenue grew 21% year-on-year to INR 1180 crore.
- Profit after tax increased 31% to INR 335 crore with EBITDA growth of 20%.
- General Medicines brands outperformed markets with Evolution Index (EI) >100.
- New Calpol 500 Suspension and Eltroxin 62.5 mcg & 150 mcg line extensions introduced.
- Vaccines business led private paediatric segment and expanded adult vaccination uptake.
- Oncology portfolio growth driven by Jemperli and Zejula’s full-year commercialization impact and introduction of BLENREP for multiple myeloma.
Key Data Snapshot
What happened
- GSK India reported Q2 FY2027 financial results with revenues of INR 1180 crore and profit after tax of INR 335 crore.
- The company achieved 21% revenue growth and 31% PAT increase year over year.
- Growth was driven by General Medicines, Vaccines, and Oncology portfolios supported by new product introductions and lifecycle management.
Key details
- General Medicines portfolio outperformed market with Evolution Index greater than 100 for promoted brands including Augmentin, Calpol, Ceftum, and T-bact.
- Introduced Calpol 500 Suspension and Eltroxin 62.5 mcg and 150 mcg line extensions for more precise dosing.
- Vaccines business strengthened leadership in private paediatric market and increased adult vaccination adoption, particularly Shingrix uptake for adults over 50.
- Oncology portfolio includes Jemperli and Zejula benefiting from full year in market; launched BLENREP as anti-BCMA ADC for adult multiple myeloma patients.
- Financial performance includes 20% EBITDA growth amid favorable base effect due to last year's supply constraints and GST transition.
Strategic context
- Company focused on innovation-led portfolio expansion and commercial excellence.
- Advancing adult immunization awareness and healthy ageing initiatives highlighted by Guinness World Record event.
- Efforts ongoing to build supply chain resilience through diversified sourcing, contingency planning, and improved operation visibility amid geopolitical inflation and supply risks.
- Preparing late-stage pipeline assets and simplifying operating models in line with global strategic priorities.
Regulatory and governance context
- BLENREP (belantamab mafodotin) approved in India for relapsed or refractory multiple myeloma after at least one prior therapy as per prescribing information dated 15-Apr-2026.
- Company continued adherence to regulatory standards in product launch and public health communications.
Highlights
- Q2 FY2027 revenue grew 21% year-on-year to INR 1180 crore.
- Profit after tax increased 31% to INR 335 crore with EBITDA growth of 20%.
- General Medicines brands outperformed markets with Evolution Index (EI) >100.
- New Calpol 500 Suspension and Eltroxin 62.5 mcg & 150 mcg line extensions introduced.
- Vaccines business led private paediatric segment and expanded adult vaccination uptake.
- Oncology portfolio growth driven by Jemperli and Zejula’s full-year commercialization impact and introduction of BLENREP for multiple myeloma.
Disclosures
- Blender Prescribing Information, India. Version: BRP/PI/IN/2026/01, dated 15-Apr-2026
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Biocon Limited Reports Q2 FY2027 Profit of Rs. 917 Million and Announces New CTO Appointment
Biocon Limited disclosed its unaudited standalone financial results for the quarter and half year ending September 30, 2026, with a quarterly profit of Rs. 917 million. The board also approved the resignation of CTO Dr. Mandar Shrikant Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as CTO starting January 1, 2027.
Read Full Story
Biocon Reports Q2 FY27 Total Income of Rs 4,423 Crore With Biopharma Revenue Up 5% and $400 Million Pertuzumab Deal
Biocon Limited announced consolidated total income of Rs 4,423 crore for the second quarter of fiscal year 2027, with biopharma revenues increasing by 5% year-on-year to Rs 3,583 crore. The company's EBITDA was reported at Rs 865 crore and net profit at Rs 41 crore. A significant highlight includes securing a 10-year biosimilar Pertuzumab PDP partnership in Brazil valued at about USD 400 million.
Read Full Story
Zydus Lifesciences Posts Rs. 79,096 Million Revenue in Q2 FY27 with Net Profit at Rs. 9,255 Million
Zydus Lifesciences Limited reported strong revenue growth of 29% year-on-year in Q2 FY27 at Rs. 79,096 million, driven by its branded pharma businesses in India, North America, and international markets. However, net profit declined 27% to Rs. 9,255 million, and EBITDA dropped 6% to Rs. 18,945 million, reflecting cost and margin pressures.
Read Full Story
